Vera Therapeutics
VERA
229 hedge funds and large institutions have $2.92B invested in Vera Therapeutics in 2026 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 94 increasing their positions, 65 reducing their positions, and 29 closing their positions.
1,136% more call options, than puts
Call options by funds: $42.9M | Put options by funds: $3.47M
62% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 29
45% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 65
7% more funds holding
Funds holding: 214 → 229 (+15)
14.54% less ownership
Funds ownership: 115.77% → 101.23% (-15%)
22% less capital invested
Capital invested by funds: $3.75B → $2.92B (-$829M)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$55.4M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$35.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.6M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
+$19.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$66.2M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$40.8M |
| 3 |
EP
Eversept Partners
New York
|
-$38.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$38.3M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$23.9M |
VERA Hedge Fund Activity: Q1 2026 in Review
229 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q1 2026, worth a combined $2.92B — down 22% from $3.75B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new VERA positions and 29 closed out — a net gain of 18 holders — while 94 added to existing stakes and 65 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $55.4M. The largest seller was Holocene Advisors, exiting entirely with an estimated $66.2M sold.
- 229 institutional investors held Vera Therapeutics (VERA) as of Q1 2026, up from 214 in Q4 2025.
- Funds reported $2.92B of Vera Therapeutics stock for Q1 2026, down 22% quarter-over-quarter.
- 47 funds opened new Vera Therapeutics positions in Q1 2026 and 29 closed out, a net change of +18 holders.
- The largest Vera Therapeutics buyer in Q1 2026 was Deep Track Capital, an estimated $55.4M added.
- The largest Vera Therapeutics seller in Q1 2026 was Holocene Advisors, an estimated $66.2M sold.
Based on aggregated 13F filings for Q1 2026.